HuGAL-FR21
Based on 1 Customer Validation
HuGAL-FR21 is a humanized antiFGFR2IIIb IgG1 monoclonal antibody. HuGAL-FR21 can block the binding of FGF2, FGF7, and FGF10 to FGFR2IIIb and inhibit FGF-induced phosphorylation of FGFR2IIIb. HuGAL-FR21 can downregulate the expression of FGFR2 in SNU-16 cells. HuGAL-FR21 shows the significant anti-tumor activity in athymic nude mice bearing gastric cancer xenograft models. HuGAL-FR21 can be used for research on cancer such as gastric cancer.
For research use only. We do not sell to patients.
- Purity : 97.80%
- Molecular Weight:143.79 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
FGFR2 |
In Vitro
HuGAL-FR21 (0.001-1 μg/mL) can specifically bind to FGFR2IIIb (EC50 approximately 20 pM) and its mutant S252W in SNU-16 cells[1].
HuGAL-FR21 (0.01-100 μg/mL) effectively blocks the binding of FGFR2IIIb (IC50 approximately 1.5-3 μg/mL) to FGF2, FGF7, and FGF10[1].
HuGAL-FR21 (10 μg/mL, 30 min) effectively blocks FGF7 induced phosphorylation and significantly inhibits FGF2 induced phosphorylation in SNU-16 cells[1].
HuGAL-FR21 (10 μg/mL, 2-24 h) downregulates FGFR2 protein levels in SNU-16 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SNU-16 cells
-
Concentration:10 μg/mL
-
Incubation Time:2, 8 and 48 h
-
Result:Reduced the level of FGFR2 protein by approximately 50%.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5×106 SNU-16 or OCUM-2M cells injected female athymic nude mice (5-6 weeks)[1]
-
Dosage:0.5, 1, 2.5 and 5 mg/kg in SNU-16 model, 1 and 2.5 mg/kg in OCUM-2M model
-
Administration:Intraperitoneal injection (i.p.); twice weekly for 25 days in SNU-16 model and 30 days in OCUM-2M model
-
Result:Significantly inhibited the growth of SNU-16 and OCUM-2M tumors.
Did not show any other obvious toxicity.
- Kinase activity and phosphorylation assays
- Western Blot
- RNA extraction experimental
- Patient-Derived Xenograft (PDX)
- Splenic/Portal-Vein Liver Metastasis Xenograft
- Protocol for Kinase activity and phosphorylation assays
- Subcutaneous Cell-Line-Derived Xenograft
- Orthotopic Cell-Line Xenograft
- Intraperitoneal/Peritoneal Dissemination Xenograft
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Molecular Weight 143.79 kDa
-
Color Colorless to light yellow
-
SMILES
N/A
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
HuGAL-FR21 Related Classifications
HY-P991584 Related Classifications
Powered by Bioz